Ketorolac/phenylephrine

Drug Profile

Ketorolac/phenylephrine

Alternative Names: Omidria; OMS-302; OMS-302-PE; Phenylephrine and ketorolac injection 1%/0.3%; Phenylephrine/ketorolac

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Omeros Corporation
  • Class Analgesics; Anti-inflammatories; Antihypotensives; Decongestants; Ethanolamines; Eye disorder therapies; Indoles; Mydriatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Miosis; Postoperative pain

Most Recent Events

  • 08 Aug 2017 Omeros Corporation files sNDA for Posteoperative pain (In children, In infants, In neonates) and Miosis (In children, In infants, In neonates, Prevention) in USA before August 2017
  • 16 Mar 2017 Omeros Corporation announces intention to submit sNDA to US FDA for label language expansion covering the use of ketorolac/phenylephrine for patients of any age
  • 21 Nov 2016 Efficacy and safety data from a phase III trial in Miosis (In children, In infants, In neonates, Prevention) and Postoperative pain (In children, In infants, In neonates) released by Omeros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top